Parallax Volatility Advisers’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-15,000
| Closed | -$2.76M | – | 1471 |
|
|
2025
Q4 | $2.76M | Hold |
15,000
| – | – | 0.01% | 855 |
|
|
2025
Q3 | $2.3M | Buy |
+15,000
| New | +$2.27M | ﹤0.01% | 883 |
|
|
2025
Q2 | – | Sell |
-43,100
| Closed | -$6.34M | – | 1557 |
|
|
2025
Q1 | $6.34M | Sell |
43,100
-37,500
| -47% | -$5.43M | 0.02% | 557 |
|
|
2024
Q4 | $10.6M | Buy |
80,600
+72,050
| +843% | +$10.1M | 0.02% | 551 |
|
|
2024
Q3 | $1.33M | Buy |
8,550
+5,100
| +148% | +$823K | ﹤0.01% | 1272 |
|
|
2024
Q2 | $538K | Sell |
3,450
-111,150
| -97% | -$16.7M | ﹤0.01% | 1423 |
|
|
2024
Q1 | $15.5M | Buy |
114,600
+88,550
| +340% | +$11.7M | 0.03% | 378 |
|
|
2023
Q4 | $3.51M | Sell |
26,050
-3,900
| -13% | -$507K | 0.01% | 957 |
|
|
2023
Q3 | $4.06M | Sell |
29,950
-134,350
| -82% | -$18.3M | 0.01% | 845 |
|
|
2023
Q2 | $23.5M | Buy |
164,300
+157,750
| +2,408% | +$23.2M | 0.05% | 306 |
|
|
2023
Q1 | $909K | Sell |
6,550
-28,700
| -81% | -$3.86M | ﹤0.01% | 1540 |
|
|
2022
Q4 | $4.78M | Sell |
35,250
-38,800
| -52% | -$4.87M | 0.01% | 1045 |
|
|
2022
Q3 | $8.12M | Buy |
74,050
+32,250
| +77% | +$4.09M | 0.01% | 830 |
|
|
2022
Q2 | $5.52M | Buy |
41,800
+27,750
| +198% | +$3.64M | 0.01% | 937 |
|
|
2022
Q1 | $1.86M | Sell |
14,050
-2,650
| -16% | -$318K | ﹤0.01% | 1390 |
|
|
2021
Q4 | $1.95M | Sell |
16,700
-19,200
| -53% | -$2.26M | ﹤0.01% | 1658 |
|
|
2021
Q3 | $4.31M | Buy |
35,900
+30,532
| +569% | +$3.55M | ﹤0.01% | 1303 |
|
|
2021
Q2 | $643K | Buy |
+5,368
| New | +$589K | ﹤0.01% | 2100 |
|
|
2021
Q1 | – | Sell |
-6,150
| Closed | -$615K | – | 3240 |
|
|
2020
Q4 | $615K | Sell |
6,150
-39,650
| -87% | -$4.2M | ﹤0.01% | 2403 |
|
|
2020
Q3 | $5.02M | Buy |
45,800
+40,600
| +781% | +$4.52M | ﹤0.01% | 1312 |
|
|
2020
Q2 | $549K | Buy |
+5,200
| New | +$537K | ﹤0.01% | 1945 |
|
|
2019
Q1 | – | Sell |
-100
| Closed | -$8K | – | 2766 |
|
|
2018
Q4 | $8K | Sell |
100
-400
| -80% | -$31.2K | ﹤0.01% | 2529 |
|
|
2018
Q3 | $40K | Buy |
+500
| New | +$37.8K | ﹤0.01% | 1941 |
|
|
2018
Q2 | – | Sell |
-200
| Closed | -$14K | – | 2107 |
|
|
2018
Q1 | $14K | Buy |
+200
| New | +$13.9K | ﹤0.01% | 1767 |
|
|
2017
Q3 | – | Sell |
-164,550
| Closed | -$11.2M | – | 2083 |
|
|
2017
Q2 | $11.2M | Buy |
164,550
+136,750
| +492% | +$8.93M | 0.02% | 374 |
|
|
2017
Q1 | $1.73M | Buy |
+27,800
| New | +$1.62M | ﹤0.01% | 922 |
|
Other funds holding AZN
IA
Parallax Volatility Advisers's AZN Position: Q1 2026 in Review
Parallax Volatility Advisers sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 63,249 shares — an estimated $11.6M sold.
Parallax Volatility Advisers first reported a position in AZN in Q4 2015 and held it in 27 quarters. The position peaked at $11.6M in Q4 2025. 1,386 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Parallax Volatility Advisers reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
- Parallax Volatility Advisers sold 63,249 AstraZeneca shares in Q1 2026, an estimated $11.6M.
- Parallax Volatility Advisers first reported a position in AstraZeneca in Q4 2015 and held it in 27 quarters.
- Parallax Volatility Advisers's AstraZeneca position peaked at $11.6M in Q4 2025.
- 1,386 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.